Get started
ROIVANT SCIENCES LIMITEDROIVANT SCIENCES LIMITEDROIVANT SCIENCES LIMITED

ROIVANT SCIENCES LIMITED

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

87S chart


Full chart

Key facts today

Roivant Sciences posted a fiscal Q2 net loss of $0.31 per share, improving from a $0.40 loss last year. Net revenue for the quarter was $4.5 million, up from $3.6 million a year earlier.
Roivant Sciences is scheduled to report earnings before the opening bell.
Analyze the impactAnalyze the impact

87S upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪8.24 B‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
2.11
Basic EPS (TTM)
5.52 EUR
Net income (FY)
‪4.03 B‬ EUR
Revenue (FY)
‪115.66 M‬ EUR
Shares float
‪376.16 M‬
Beta (1Y)
0.62

Employees


Employees (FY)
908
Change (1Y)
+4 +0.44%
Revenue / Employee (1Y)
‪137.44 K‬ EUR
Net income / Employee (1Y)
‪4.79 M‬ EUR

About Roivant Sciences Ltd.


Sector
Health Technology
CEO
Matthew Gline
Headquarters
London
Website
roivant.com
Founded
2021
FIGI
BBG012VH87C5
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

87S news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 87S is 11.01 EUR — it has decreased by −0.22% in the past 24 hours. Watch ROIVANT SCIENCES LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange ROIVANT SCIENCES LIMITED stocks are traded under the ticker 87S.
87S stock has risen by 5.05% compared to the previous week, the month change is a 3.05% rise, over the last year ROIVANT SCIENCES LIMITED has showed a 35.03% increase.
We've gathered analysts' opinions on ROIVANT SCIENCES LIMITED future price: according to them, 87S price has a max estimate of 20.37 EUR and a min estimate of 11.58 EUR. Watch 87S chart and read a more detailed ROIVANT SCIENCES LIMITED stock forecast: see what analysts think of ROIVANT SCIENCES LIMITED and suggest that you do with its stocks.
87S reached its all-time high on Jul 14, 2023 with the price of 12.60 EUR, and its all-time low was 2.71 EUR and was reached on May 12, 2022. View more price dynamics on 87S chart.
See other stocks reaching their highest and lowest prices.
87S stock is 1.95% volatile and has beta coefficient of 0.62. Track ROIVANT SCIENCES LIMITED stock price on the chart and check out the list of the most volatile stocks — is ROIVANT SCIENCES LIMITED there?
Today ROIVANT SCIENCES LIMITED has the market capitalization of ‪8.20 B‬, it has increased by 4.46% over the last week.
Yes, you can track ROIVANT SCIENCES LIMITED financials in yearly and quarterly reports right on TradingView.
ROIVANT SCIENCES LIMITED is going to release the next earnings report on Feb 17, 2025. Keep track of upcoming events with our Earnings Calendar.
87S earnings for the last quarter are −0.26 EUR per share, whereas the estimation was −0.22 EUR resulting in a −15.14% surprise. The estimated earnings for the next quarter are −0.27 EUR per share. See more details about ROIVANT SCIENCES LIMITED earnings.
ROIVANT SCIENCES LIMITED revenue for the last quarter amounts to ‪4.02 M‬ EUR, despite the estimated figure of ‪43.75 M‬ EUR. In the next quarter, revenue is expected to reach ‪27.54 M‬ EUR.
87S net income for the last quarter is ‪88.97 M‬ EUR, while the quarter before that showed ‪−140.05 M‬ EUR of net income which accounts for 163.53% change. Track more ROIVANT SCIENCES LIMITED financial stats to get the full picture.
No, 87S doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 12, 2024, the company has 908.00 employees. See our rating of the largest employees — is ROIVANT SCIENCES LIMITED on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ROIVANT SCIENCES LIMITED EBITDA is ‪−955.87 M‬ EUR, and current EBITDA margin is −847.72%. See more stats in ROIVANT SCIENCES LIMITED financial statements.
Like other stocks, 87S shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ROIVANT SCIENCES LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ROIVANT SCIENCES LIMITED technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ROIVANT SCIENCES LIMITED stock shows the buy signal. See more of ROIVANT SCIENCES LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.